Detalhe da pesquisa
1.
Population-based utilization and costs associated with tyrosine kinase inhibitors for first-line treatment of chronic myelogenous leukemia among elderly patients.
J Manag Care Spec Pharm
; 26(12): 1494-1504, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-33251998